Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Trent Talks Through Potential Clinical Applications and Future Directions for MRD in GIST

July 31st 2023

Dr Trent discusses the current role and significance of using MRD in gastrointestinal stromal tumor, current guidelines around mutation testing, and research seeking to expand the targeted therapy armamentarium.

Camidge and Abbott Discuss the Role of the Biotechnology Analyst in Drug Development

July 27th 2023

In this episode of ‘How This is Building Me,’ Drs Camidge and Abbott discuss the road from bench scientist to biotechnology analyst, rules and regulations in the industry, and more.

Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL

July 24th 2023

Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.

Khan and Kwendakwema Discuss Financial Toxicity in Patients With Cancer

July 20th 2023

Drs Khan and Kwendakwema discuss the methods and design of two studies investigating adverse financial events in patients with cancer, the future implications of these findings, and the importance of continued investigation in this area.

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023

Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.

Lunning and Abramson Spotlight Developments and Challenges in LBCL Research and Management

July 13th 2023

Dr Lunning sits down with Jeremy Abramson, MD, to discuss treatment options for patients with LBCL following relapse on their initial therapies, the potential role of surveillance imaging in certain subsets of this population, and the challenging differences that arise when treating patients with cellular therapy in clinical trials vs in the real-world setting.

FDA Approval Insights: Avapritinib in Indolent Systemic Mastocytosis

July 10th 2023

Dr Gotlib discusses the significance of the FDA approval of avapritinib in indolent systemic mastocytosis, key findings from the PIONEER trial, and the quality of life benefits that avapritinib provides for patients in this population.

King Describes Unmet Needs and the Role of Surgical Resection in Residual Non-RP Testicular Cancer

July 6th 2023

Dr King discusses the need for improved guidance when determining the appropriate management strategy for patients with residual nonretroperitoneal testicular cancer and findings from a study on the association between the presence of teratoma in the primary orchiectomy and the rate of teratoma in this disease.

Kremyanskaya Highlights the Benefits of BET Inhibitors in Myelofibrosis

July 3rd 2023

Dr Kremyanskaya discusses the results from cohort 1 of the MANIFEST trial in treatment-naïve myelofibrosis, differentiating features of pelabresib and recently approved JAK inhibitors, and next steps for the investigation of BET inhibitors in this population.

Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023

June 29th 2023

Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.

Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer

June 26th 2023

In this episode of ‘How This is Building Me,’ Dr Camidge is rejoined by Dr Cetnar to discuss the good, the bad, and the ugly of the lung cancer data that were presented at the 2023 ASCO Annual Meeting.

Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care

June 22nd 2023

Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and the importance of connecting patients with a multidisciplinary team to provide necessary resources and care.

Reuss Reviews the Development of LP-300 in Advanced NSCLC

June 19th 2023

Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

June 12th 2023

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.

Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research

June 8th 2023

Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, and ongoing research regarding potential genetic links to this rare cancer.

Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology

June 5th 2023

Dr Raskin discusses the road from fellow to fellowship director at Massachusetts General Hospital, the importance of transparency in a program amid increasing emphasis on health and wellness, and the skills a successful program should impart on their trainees.

Camidge and Weickhardt Consider Oncology Practice and Patient Care From an International Perspective

June 1st 2023

In this episode of How This Is Building Me, Drs Camidge and Weickhardt discuss the span of countries Dr Weickhardt’s medical training and career has led him to, the ins and outs of becoming a practicing oncologist in Australia vs the United States, and the importance of discerning patient needs and preferences to earn patient trust and deliver effective, personalized care across the globe.

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin in patients with this disease, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients.

Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid Tumors

May 25th 2023

Drs Gottschalk and Krenciute discuss the difficulties of translating successes with CAR T-cell therapy in adults to the pediatric population; ongoing research with investigational products that could reduce T-cell exhaustion, burnout, and the time from bench to bedside; and expectations for the future of cellular therapy in oncology.